GSK plc

Symbol: GSK.L

LSE

1661.8

GBp

Market price today

  • 16.1571

    P/E Ratio

  • 76.2975

    PEG Ratio

  • 67.44B

    MRK Cap

  • 0.03%

    DIV Yield

GSK plc (GSK-L) Stock Price & Analysis

Shares Outstanding

4078.02M

Gross Profit Margin

0.72%

Operating Profit Margin

0.23%

Net Profit Margin

0.15%

Return on Assets

0.08%

Return on Equity

0.34%

Return on Capital Employed

0.18%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Ms. Emma Natasha Walmsley
Full-time employees:69400
City:Brentford
Address:980 Great West Road
IPO:1988-07-01
CIK:

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

General Outlook

In simple terms, GSK plc has 4078.02 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.724% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.232%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.146%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.077% return, is a testament to GSK plc's adeptness in optimizing resource deployment. GSK plc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.338%. Furthermore, the proficiency of GSK plc in capital utilization is underscored by a remarkable 0.184% return on capital employed.

Stock Prices

GSK plc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1718.5, while its low point bottomed out at $1673. This variance in figures offers investors a lucid insight into the roller-coaster ride that is GSK plc's stock market.

Liquidity Ratios

Analyzing GSK.L liquidity ratios reveals its financial health of the firm. The current ratio of 86.69% gauges short-term asset coverage for liabilities. The quick ratio (57.37%) assesses immediate liquidity, while the cash ratio (14.06%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio86.69%
Quick Ratio57.37%
Cash Ratio14.06%

Profitability Ratios

GSK.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 17.94% underscores its earnings before tax deductions. The effective tax rate stands at 13.67%, revealing its tax efficiency. The net income per EBT, 81.32%, and the EBT per EBIT, 77.39%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 23.18%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin17.94%
Effective Tax Rate13.67%
Net Income per EBT81.32%
EBT per EBIT77.39%
EBIT per Revenue23.18%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.87, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding57
Days of Inventory Outstanding245
Operating Cycle332.03
Days of Payables Outstanding629
Cash Conversion Cycle-297
Receivables Turnover4.22
Payables Turnover0.58
Inventory Turnover1.49
Fixed Asset Turnover3.12
Asset Turnover0.53

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.83, and free cash flow per share, 1.24, depict cash generation on a per-share basis. The cash per share value, 1.01, showcases liquidity position. A payout ratio of 0.50 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.24, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.83
Free Cash Flow per Share1.24
Cash per Share1.01
Payout Ratio0.50
Operating Cash Flow Sales Ratio0.24
Free Cash Flow to Operating Cash Flow Ratio0.68
Cash Flow Coverage Ratio0.42
Short Term Coverage Ratio2.84
Capital Expenditure Coverage Ratio3.12
Dividend Paid and Capex Coverage Ratio1.60
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 30.37%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.28, we discern the balance between debt and equity financing. The long-term debt to capitalization, 52.27%, and total debt to capitalization, 56.22%, ratios shed light on its capital structure. An interest coverage of 9.44 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio30.37%
Debt Equity Ratio1.28
Long Term Debt to Capitalization52.27%
Total Debt to Capitalization56.22%
Interest Coverage9.44
Cash Flow to Debt Ratio0.42
Company Equity Multiplier4.23

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 7.48, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.22, reflects the portion of profit attributed to each share. The book value per share, 3.29, represents the net asset value distributed per share, while the tangible book value per share, -2.17, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share7.48
Net Income Per Share1.22
Book Value Per Share3.29
Tangible Book Value Per Share-2.17
Shareholders Equity Per Share3.29
Interest Debt Per Share4.38
Capex Per Share-0.58

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 3.42%, indicates top-line expansion, while the gross profit growth, 7.50%, reveals profitability trends. EBIT growth, 8.71%, and operating income growth, 8.71%, offer insights into operational profitability progression.

cards.indicatorcards.value
Revenue Growth3.42%
Gross Profit Growth7.50%
EBIT Growth8.71%
Operating Income Growth8.71%
Net Income Growth0.14%
Weighted Average Shares Growth0.65%
Weighted Average Shares Diluted Growth0.66%
Dividends per Share Growth-35.60%
Operating Cash Flow Growth-14.25%
Free Cash Flow Growth-22.18%
10-Year Revenue Growth per Share9.14%
5-Year Revenue Growth per Share-4.53%
3-Year Revenue Growth per Share-12.62%
10-Year Operating CF Growth per Share-16.16%
5-Year Operating CF Growth per Share-26.86%
3-Year Operating CF Growth per Share-26.12%
10-Year Net Income Growth per Share-13.53%
5-Year Net Income Growth per Share31.96%
3-Year Net Income Growth per Share-15.79%
10-Year Shareholders Equity Growth per Share81.94%
5-Year Shareholders Equity Growth per Share197.00%
3-Year Shareholders Equity Growth per Share-10.11%
10-Year Dividend per Share Growth per Share-41.76%
5-Year Dividend per Share Growth per Share-44.49%
3-Year Dividend per Share Growth per Share-44.49%
Receivables Growth4.05%
Inventory Growth6.84%
Asset Growth-1.90%
Book Value per Share Growth25.13%
Debt Growth-14.15%
R&D Expense Growth-4.43%
SGA Expenses Growth7.67%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 73,844,104,000, captures the company's total value, considering both debt and equity. Income quality, 1.29, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.31, gauges operational efficiency, while the research and development to revenue, 17.29%, highlights investment in innovation. The ratio of intangibles to total assets, 36.57%, indicates the value of non-physical assets, and capex to operating cash flow, -36.93%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value73,844,104,000
Income Quality1.29
Sales General and Administrative to Revenue0.31
Research and Development to Revenue17.29%
Intangibles to Total Assets36.57%
Capex to Operating Cash Flow-36.93%
Capex to Revenue-7.73%
Capex to Depreciation-102.18%
Stock-Based Compensation to Revenue1.01%
Graham Number9.49
Return on Tangible Assets13.17%
Graham Net Net-8.08
Working Capital-2,424,000,000
Tangible Asset Value-8,784,000,000
Net Current Asset Value-27,566,000,000
Invested Capital1
Average Receivables7,259,000,000
Average Payables9,990,000,000
Average Inventory5,322,000,000
Days Sales Outstanding89
Days Payables Outstanding149
Days of Inventory On Hand221
ROIC20.19%
ROE0.37%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.23, and the price to book ratio, 5.23, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.36, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 14.38, and price to operating cash flows, 9.75, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.23
Price to Book Ratio5.23
Price to Sales Ratio2.36
Price Cash Flow Ratio9.75
Price Earnings to Growth Ratio76.30
Enterprise Value Multiple5.80
Price Fair Value5.23
Price to Operating Cash Flow Ratio9.75
Price to Free Cash Flows Ratio14.38
Price to Tangible Book Ratio4.40
Enterprise Value to Sales2.43
Enterprise Value Over EBITDA7.95
EV to Operating Cash Flow11.63
Earnings Yield8.39%
Free Cash Flow Yield6.81%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of GSK plc (GSK.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 16.157 in 2024.

What is the ticker symbol of GSK plc stock?

The ticker symbol of GSK plc stock is GSK.L.

What is company IPO date?

IPO date of GSK plc is 1988-07-01.

What is company current share price?

Current share price is 1661.800 GBp.

What is stock market cap today?

The market cap of stock today is 67439002749.000.

What is PEG ratio in 2024?

The current 76.298 is 76.298 in 2024.

What is the number of employees in 2024?

In 2024 the company has 69400.